Poly Medicure Limited has informed the Exchange about Transcript
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure reported Q1 FY26 consolidated revenue of Rs. 403 crore, up ~5% YoY, with EBITDA margin at 26.3% (vs 27% last year) and PAT rising to Rs. 93 crore from Rs. 74 crore. Domestic revenue grew 20% (private sector +25%, government -10%) to Rs. 126 crore, while international revenue dipped 1% to Rs. 275 crore with Europe declining 6.7% due to inventory correction and tariff-related uncertainty. Management lowered FY26 international growth guidance to 5-10% from 12-15% but reiterated 30% domestic growth and 25-27% EBITDA margin guidance. Key business updates include signing of two CDMO contracts (one US, one Hong Kong-based), establishment of a wholly-owned subsidiary in Brazil, renal business growth of 46%, implantation of 1,350 drug-eluting stents, and benefit from the UK FTA reducing duty to 0%.
Mixed quarter with strong domestic momentum offsetting temporary international headwinds; lower international guidance may weigh on near-term sentiment, but strong cash position of Rs. 1,249 crore, new product pipeline across cardiology and critical care, and CDMO opportunity support the long-term growth story.